A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

by | Jun 15, 2026 | Clinical Trials | 0 comments

​ Conditions: ER-Positive HER2-Negative Breast Cancer

Interventions: Drug: Camizestrant; Drug: Ribociclib

Sponsors: AstraZeneca; ICON plc

Not yet recruiting Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Drug: Camizestrant; Drug: Ribociclib
Sponsors: AstraZeneca; ICON plc
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *